Volume 54, Number 11
Complexities of treating M. abscessus pulmonary disease include drug resistance, frequent drug-related adverse effects, variable treatment outcome definitions and poor treatment outcomes among patients with underlying chronic lung diseases.
Illustration by Maria De-Castro
Editorial
Leveraging real-world data to develop long-term follow-up programmes for childhood cancer survivors
In this issue of the Annals, Lam Shang Leen et al. comprehensively audited the late effects experienced by 485 childhood cancer survivors who visited...
Editorial
Mycobacterium abscessus treatment: From empiricism to mechanism
Singapore has reached an inflection point in mycobacterial disease epidemiology, where nontuberculous mycobacterial (NTM) lung infections now nearly surpass tuberculosis (TB) in both incidence...
Original Article
The reported late effects experienced by childhood cancer survivors treated in Singapore: A clinical audit
Advances in diagnostics and therapies have significantly improved paediatric cancer survival in high-income countries, with up to 90% of children living beyond 5 years...
Review Article
Treatment outcomes in Mycobacterium abscessus pulmonary disease: A systematic review
Mycobacterium abscessus complex (MABC) is a group of rapidly growing, non-tuberculous mycobacteria (NTM) increasingly recognised as clinically significant pathogens worldwide.1,2 The complex comprises 3...
Review Article
Advancing cardiology pharmacy practice: A position paper on physician-led, pharmacist-enabled model for sustainable cardiovascular care
Cardiovascular disease (CVD) remains one of Singapore’s leading causes of morbidity and mortality, accounting for a growing proportion of hospital admissions and chronic disease...
MOST VIEWED ARTICLES
Letter to the Editor

